News
3 Major Regional Banks to Bet on Amid Favorable Industry Tailwinds
Abercrombie & Fitch (ANF) Surpasses Q4 Earnings and Revenue Estimates
Abercrombie & Fitch (ANF) came out with quarterly earnings of $3.68 per share, beating the Zacks Consensus Estimate of $3.56 per share. This compares to earnings of $3.57 per share a year ago. These
Advanced Flower Capital Inc. (AFCG) Reports Q4 Loss, Lags Revenue Estimates
Advanced Flower Capital Inc. (AFCG) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.29 per share a year ago
3 Top-Ranked Vanguard Mutual Funds You Should Consider Buying
Vanguard, one of the world’s largest asset management corporations, was founded by John C. Bogle on May 1, 1975. Headquartered in Valley Forge, PN, the company had $11 trillion in assets under
Holley Inc. (HLLY) Misses Q4 Earnings Estimates
Holley Inc. (HLLY) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.11 per share a year ago. These
Daktronics (DAKT) Misses Q3 Earnings Estimates
Daktronics (DAKT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.01 per share a year ago. These figures
New Strong Sell Stocks for March 4th
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
BKV Corporation BKV is an energy company, which produce natural gas from its owned and operated upstream businesses. The
JD Gears Up to Report Q4 Earnings: What's in Store for the Stock?
JD.com JD is scheduled to release fourth-quarter 2025 results on March 5.The Zacks Consensus Estimate for JD’s fourth-quarter revenues is pegged at $50.22 billion, indicating an increase of 5.64% on
Here's How Much a $1000 Investment in HubSpot Made 10 Years Ago Would Be Worth Today
For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and
Here's How Much You'd Have If You Invested $1000 in Fair Isaac a Decade Ago
For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and
If You Invested $1000 in ATI a Decade Ago, This is How Much It'd Be Worth Now
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across
Will Petrobras Pull Off Q4 Earnings Beat on Strong Production?
Petroleo Brasileiro S.A., or Petrobras PBR, is set to release fourth-quarter 2025 results on March 5. The Zacks Consensus Estimate for the to-be-reported quarter is a profit of 57 cents per share on
Chewy Expands Pet Health Platform: Is CHWY a Long-Term Play?
Chewy, Inc. CHWY built its brand as a pure-play pet e-commerce platform spanning food, treats, supplies and medications. Now the company is pushing deeper into pet health and services that can lift
Why Home Depot Expects Second Half Comps to Outperform First Half
The Home Depot, Inc. HD expects comparable sales growth in fiscal 2026 to be stronger in the second half than in the first half. Management expects comparable sales to be flat to up 2% for the
Dycom Industries (DY) Q4 Earnings and Revenues Surpass Estimates
Dycom Industries (DY) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.17 per share a year ago. These
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint (EYPT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.64 per share a year ago. These figures are
D-Wave Quantum's Q4 Bookings Fall Y/Y: How Does the Year Ahead Look?
D-Wave Quantum QBTS reported bookings of $13.4 million in the fourth quarter of 2025, down 27% compared to the prior-year period, which benefited from an eight-figure system sale. On a sequential
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago. These
The Real Brokerage Inc. (REAX) Reports Q4 Loss, Beats Revenue Estimates
The Real Brokerage Inc. (REAX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago. These
Is This the Right Time to Hold Labcorp Stock in Your Portfolio?
Labcorp Holdings Inc. LH, or Labcorp, is well-poised for growth in the coming quarters due to its test expansion in strategic high-growth areas, including neurology and autoimmune disease. The
BigBear.ai Stock Is Down Big, But Smart Money Is Quietly Buying
There are reasons why BigBear.ai (NYSE: BBAI) stock struggled to gain traction in 2025, eventually falling to long-term lows, but the story is changing in 2026. Issues keeping analysts and
3 Resilient Sales Growth Stocks for Navigating a Risk-Off Market
This year started on a weak note. U.S. markets have seen bouts of selling tied to shifting AI expectations and geopolitical tensions, especially Middle East risks and oil-shock fears, prompting
Riskified (RSKD) Q4 Earnings and Revenues Top Estimates
Riskified (RSKD) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.06 per share a year ago. These figures
Bath & Body Works (BBWI) Q4 Earnings and Revenues Surpass Estimates
Bath & Body Works (BBWI) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.09 per share a year ago. These
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
Acadia Pharmaceuticals ACAD announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has formally adopted a negative opinion recommending


